Table 1.
Patient characteristics and treatment results from selected clinical trials
| Study group | Years of study | No. of patients | Age range (years) | T-cell ALL (%) | 5-year cumulative rate of any relapse (%) | 5-year EFS (%) | 5-year survival (%) | Data source |
|---|---|---|---|---|---|---|---|---|
| AIEOP-BFM 2000 | 2000–2006 | 4,839 | 1–17 | 13.2 | 13.2 | 81.4±0.6 | 91.9±0.4 | Moricke et al.2 |
| CoALL-07–03 | 2003–2010 | 743 | 1–18 | 12.9 | NA | 83±0.3 | NA | Escherich et al.3 |
| COG | 2000–2005 | 7,153 | 0–21 | 7 | 7.22 | NA | 90.4±0.5 | Hunger et al.4 |
| DCOG-10 | 2004–2012 | 778 | 1–18 | 14.2 | 8.3 | 87±1.2 | 91.9±1.0 | Pieters et al.5 |
| DFCI 05–001 | 2005–2010 | 551 | 1–18 | 13 | 8.96 | 85 | 91 | Place et al.6 |
| EORTC 58951 | 1998–2008 | 1947 | 1–18 | 15.2 | 14.7 | 82.6±0.9 | 89.7±0.7 | Domenech et al.7 |
| IC-BFM 2002 | 2002–2007 | 5,060 | 1–18 | 13.3 | 19 | 74±1 | 82±1 | Stary et al.8 |
| JCCLSG ALL 2000 | 2000–2004 | 305 | 1–15 | 9.8 | 17 | 79.7±2.4 | 89.2±1.8 | Yamaji et al.9 |
| Ma-Spore ALL 2003 | 2002–2011 | 556 | 0–18 | 8.8 | NA | 80.6±3.5 | 89.2±2.7 | Yeoh et al.10 |
| MRC UKALL 2003 | 2003–2011 | 3,126 | 1–25 | 12 | 8.8 | 87.3±1.4 | 91.6±1.2 | Vora et al.11 |
| NOPHO-2008 | 2008–2014 | 1,022 266 |
1–9 10–17 |
9.1 25.2 |
10 3±1 |
89±1 80±3 |
1 2 ±± 47 98 | Toft et al.12 |
| SJCRH XV | 2000–2007 | 498 | 1–18 | 15 | 9.3 | 87.3±2.9 | 93.5±1.9 | Pui et al.13 |
| TPOG | 1999–2010 | 152 | 0–18 | 7.2 | NA | 84.2±3.0 | 90.2±2.4 | Liu et al.14 |
Abbreviations: ALL, acute lymphoblastic leukemia; AIEOP, Associazione Italiana di Ematologia Pediatrica Group; BFM, Berlin-Frankfurt-Münster; CNS, central nervous system; CoALL, Cooperative ALL Study Group; COG, Children’s Oncology Group; DCOG, Dutch Children’s Oncology Group; DFCI, Dana-Farber Cancer Institute consortium; EFS, event-free survival; EORTC – CLG, European Organisation for Research and Treatment of Cancer - Children Leukemia Group; IC-BFM, Intercontinental-BFM; JCCLSG, Japanese Children’s Cancer and Leukemia Study Group; Ma-Spore, Malaysia-Singapore; MRC UKALL, Medical Research Council United Kingdom acute lymphoblastic leukemia; NA, not available; NOPHO, Nordic Society of Pediatric Hematology and Oncology; SJCRH, St. Jude Children’s Research Hospital; TPOG, Taiwan Pediatric Oncology Group.